methods largely consistent with those of the 1993 UK valuation survey.
The study by Luo and others extends the previous work of its authors, who conducted the 2002 US valuation survey for the EQ-5D, using methods largely consistent with those of the 1993 UK valuation survey. 3;4 Their new study compares the full complement of 243 EQ-5D health state scores predicted by the statistical models developed from the US and UK valuation surveys (both of which directly valued the same 42 common EQ-5D health states). Not surprisingly, like the authors' earlier comparison of the directly valued health states, the US statistical model consistently predicted health state scores that were higher than those predicted by the UK model. Over the full set of EQ-5D health states, the difference in mean scores was 0.23, as compared with the 0.11 difference found for the smaller number of directly valued states in the earlier comparison. 3 More notably, the new study found a mean difference in transitions between all pairs of health states of 0.25 for the US valuation model and 0.35 for the UK model: The range of all EQ-5D health state valuations in the US model was more compressed than in the UK model. The authors reasonably surmise that although incremental cost-effectiveness ratios (ICERs) calculated using the US model values would likely be less favorable than those using the UK model values, this result would depend on the nature of the condition under study, the severity of the health states, and the size of the health effect.
Noyes and colleagues take another step and examine the differences in results between the USand UK-valued EQ-5D statistical models in a costeffectiveness analysis. Using the US values, they reanalyze data from a clinical trial comparing 2 alternative drug therapies (initial pramipexole v. levodopa) in patients with Parkinson disease, which originally used health state values from the UK EQ-5D model (see references 15-17 in the article by Noyes and others). The comparative performance of the US-and UK-valued EQ-5D models was consistent with the simulated results that Luo and others obtained: Measured over time, the US-and UKspecific EQ-5D scores for patients with Parkinson disease followed similar trajectories, except that the US scores were higher on average. As in the simulation exercise, the range of scores using the US values was more compressed than that with the UK values. In particular, Noyes and others found greater differences between the US and UK estimates among subjects who reported problems with usual activities, pain/discomfort, or anxiety/depression than between the estimates for subjects not reporting these problems. As the authors conclude, the implications of the more compressed range of scores using the US valuation model are that the estimated 4-year gains in quality-adjusted life years (QALYs) of the experimental over the control therapy are less than half as large as those using the UK model, a much less favorable ICER ($108,000/QALY v. $43,000/QALY) and a lower probability that the experimental therapy is cost-effective at any dollar-per-QALY threshold. 2 Taken together, these 2 studies offer insight into how valuations of health states based on the USand UK-valued EQ-5D statistical models compare and where they differ most (namely, in the value placed on the worse levels in the domains of pain/ discomfort and anxiety/depression-2 of the 5 EQ-5D categories). Noyes and others demonstrate how using the more fitting set of health state values-US-specific values in a study of US patients rather than values elicited a decade earlier from UK residents-makes a difference large enough to be of potential significance for clinical practice and coverage decisions. The incremental impact and costeffectiveness of therapeutic alternatives look quite different depending on the country-specific valuations used in the analysis. Given that the absolute magnitude of any changes in health-related quality of life measured by the US-specific values will be smaller, it will be relatively more difficult to demonstrate substantial therapeutic effects using the US EQ-5D model scores than the UK scores.
Still, this implication should not be overdrawn. As Dennis Fryback commented at the publication of the US valuation survey and statistical model a few years ago, the importance of the US QALY values resides in their legitimacy as a conventional metric that will allow for standardization in measuring health outcomes in this country. 5 The absolute value of the scores or even of the estimated differences between health states is somewhat arbitrary. A corollary of this claim is that cost-effectiveness thresholds cannot be applied as absolute standards and that quite different ICERs might be considered acceptable in different countries.
One final thought about the implications of these 2 studies: The US statistical model demonstrated good responsiveness in comparison with the UK model, and the 5-domain, 3-level EuroQol instrument appears to be adequately sensitive to changes in health states for treated patients with Parkinson disease. The performance of the EQ-5D (as compared with that of more elaborate multiattribute utility scales such as the Health Utilities Index and the Quality of Well-being Scale) merits further study in terms of its ability to represent changes in healthrelated quality of life for a wide range of conditions. In the meantime, however, the US-valued EQ-5D is a sound choice for comparative effectiveness and costeffectiveness studies conducted in this country.
